Mankind Pharma Limited Moxifloxacin Export Data — India (DGFT 2022–2026)

Name: Mankind Pharma Limited Moxifloxacin Export Records India — #10 Exporter, 11 Shipments, $452.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Moxifloxacin

India Pharmaceutical Trade Intelligence

$32.8M336 Suppliers137 CountriesHS 30049099

ExportsIndia → NIGERIA44.8%India → UNITED STATES17.5%

ImportsUNITED STATES → India$160.3B BRAZIL → India$30.7B

#1 Buyer: NATIONAL TUBERCULOSIS

Mankind Pharma Limited — Moxifloxacin Exporter #10 | $452.0K Trade Value | TransData Nexus | TransData Nexus

Mankind Pharma Limited — Moxifloxacin Exporter Profile

Indian Pharmaceutical Exporter · #10 for Moxifloxacin · $452.0K export value · DGFT Verified

Mankind Pharma Limited is the #10 Indian exporter of Moxifloxacin with $452.0K in export value and 11 verified shipments. Mankind Pharma Limited holds a 1.4% market share in Moxifloxacin exports across 2 countries. The company exports 15 pharmaceutical products worth $58.3M across 10 therapeutic categories.

Mankind Pharma Limited — Moxifloxacin Export Profile: Buyers & Destinations

Mankind Pharma Limited Moxifloxacin export treemap — buyers and destination countries | TransData Nexus

Where Does Mankind Pharma Limited Export Moxifloxacin?

Country	Value	Shipments	Share
UNITED STATES	$366.9K	10	91.8%
PAKISTAN	$32.7K	1	8.2%

Mankind Pharma Limited exports Moxifloxacin to 2 countries. The largest destination is UNITED STATES accounting for 91.8% of Mankind Pharma Limited's Moxifloxacin shipments. These destinations reflect Mankind Pharma Limited's established distribution network and regulatory approvals in key markets.

Who Are the Top Buyers of Moxifloxacin from Mankind Pharma Limited?

What Moxifloxacin Formulations Does Mankind Pharma Limited Export?

Product Description / Formulation	Value	Shipments
Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% Batch No. AU7Y003 Mfg.Date JAN-2025 Exp Date DEC-2026	$116.5K	3
Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% Batch No. AU7Y002 Mfg.Date DEC-2024 Exp Date NOV-2026	$100.0K	2
Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% Batch No. AU7Y001 Mfg.Date DEC-2024 Exp Date NOV-2026	$59.7K	2
Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% Batch No. AU7Y004 Mfg.Date JAN-2025 Exp Date DEC-2026	$50.0K	1
Mahaflox-400 Tabs 1x5's {Each Film Coated Tablet Contains: Moxifloxacin Hydrochloride Equivalent to Moxifloxacin Batch N	$32.7K	1
MOXIFLOXACIN HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.5% [BATCH NO. AU7Y006 MFG.DT. 02/25 EXP DT. 01/27]	$21.6K	1
MOXIFLOXACIN HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.5% [BATCH NO. AU7Y005 MFG.DT. 02/25 EXP DT. 01/27]	$19.2K	1

Mankind Pharma Limited exports 7 distinct Moxifloxacin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% Bat with 3 shipments worth $116.5K.

How Does Mankind Pharma Limited Compare to Nearest Moxifloxacin Exporters?

Exporters ranked immediately above and below #10 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
8	ALEMBIC PHARMACEUTICALS LIMITED	$683.8K	25	1	$27.4K
9	MACLEODS PHARMACEUTICALS LIMITED	$656.3K	20	10	$32.8K
10	MANKIND PHARMA LIMITED ★	$452.0K	11	2	$41.1K
11	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$401.3K	15	6	$26.8K
13	HETERO LABS LIMITED	$260.9K	7	3	$37.3K

Mankind Pharma Limited ranks #10 among 336 Indian Moxifloxacin exporters. Average shipment value of $41.1K compared to the market average of $42.4K. The closest competitors by value are ALEMBIC PHARMACEUTICALS LIMITED and MACLEODS PHARMACEUTICALS LIMITED.

Which Indian Ports Ship Moxifloxacin Exports?

Port	Shipments	% Share
SAHAR AIR	311	12.9%
SAHAR AIR CARGO ACC (INBOM4)	263	10.9%
DELHI AIR CARGO ACC (INDEL4)	152	6.3%
DELHI AIR	132	5.5%
NHAVA SHEVA SEA (INNSA1)	126	5.2%
Bombay Air	119	4.9%
CHENNAI AIR	111	4.6%
CHENNAI AIR CARGO ACC (INMAA4)	93	3.9%

Geopolitical & Trade Policy Impact on Mankind Pharma Limited's Moxifloxacin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Mankind Pharma. The Israel-Iran conflict has led to increased tensions in the Red Sea, resulting in higher shipping costs and potential delays for exporters relying on these routes. Additionally, Houthi attacks in the region have further exacerbated shipping disruptions, impacting the timely delivery of pharmaceutical products.

Conversely, ongoing US-China trade tensions have prompted the United States to diversify its import sources, creating opportunities for Indian pharmaceutical companies to capture a larger share of the US market. Mankind Pharma's established presence and compliance with international quality standards position it favorably to leverage this shift.

In the European Union, stringent regulatory changes, such as the Falsified Medicines Directive, necessitate robust compliance measures. Mankind Pharma's commitment to quality and recent strategic initiatives, including the acquisition of BSV, enhance its ability to meet these evolving standards and maintain a competitive edge in the EU market.

Mankind Pharma Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards is paramount for pharmaceutical exporters. Mankind Pharma's adherence to guidelines set by the FDA, WHO, and EU GMP underscores its commitment to quality. The acquisition of BSV, known for its complex R&D platforms and biologics expertise, further strengthens Mankind Pharma's compliance capabilities, ensuring alignment with global quality requirements. (mankindpharma.com)

The evolving regulatory landscape, particularly in the EU with directives like the Falsified Medicines Directive, demands continuous adaptation. Mankind Pharma's proactive approach, including investments in advanced manufacturing and quality assurance systems, positions it well to navigate these changes and sustain its export growth.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Moxifloxacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Mankind Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 11 individual customs records matching Mankind Pharma Limited exporting Moxifloxacin, covering 7 formulations to 2 countries via 3 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 137+ countries, 731+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Moxifloxacin

Moxifloxacin

Mankind Pharma Limited — Moxifloxacin Exporter Profile

Mankind Pharma Limited — Moxifloxacin Export Profile: Buyers & Destinations

Where Does Mankind Pharma Limited Export Moxifloxacin?

Who Are the Top Buyers of Moxifloxacin from Mankind Pharma Limited?

What Is India's Total Moxifloxacin Export Value and How Much Does Mankind Pharma Limited Contribute?

What Is the Average Shipment Value for Mankind Pharma Limited's Moxifloxacin Exports?

How Does Mankind Pharma Limited Compare to Other Indian Moxifloxacin Exporters?

What Moxifloxacin Formulations Does Mankind Pharma Limited Export?

Regulatory Requirements: Exporting Moxifloxacin to Key Markets

United States — FDA

How Does Mankind Pharma Limited Compare to Nearest Moxifloxacin Exporters?

Which Indian Ports Ship Moxifloxacin Exports?

What Other Advanced Antibiotics Products Does Mankind Pharma Limited Export?

Geopolitical & Trade Policy Impact on Mankind Pharma Limited's Moxifloxacin Exports

Mankind Pharma Limited — Regulatory Compliance & Quality Standards

About Mankind Pharma Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Moxifloxacin Export Data from Mankind Pharma Limited

Moxifloxacin Stats

Company Overview

Top Products by Mankind Pharma Limited

Related Analysis

Need Detailed Export Data?

Data Source

LIFESTAR PHARMA LLC	UNITED STATES	$266.9K	8
LIFESTAR PHARMA LLC....	UNITED STATES	$100.0K	2
ZAHIR HADROGUL LTD.	PAKISTAN	$32.7K	1